Graduate Thesis Or Dissertation
 

Bovine Kappa-Casein Glycomacropeptide: Its Effects on the Microbiome, Inflammation and the Potential in Irritable Bowel Syndrome Management

Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/graduate_thesis_or_dissertations/sj139969r

Descriptions

Attribute NameValues
Creator
Abstract
  • Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder experienced by 10–15% of the global population, manifesting as chronic abdominal pain, bloating and inconsistent bowel habits. The search for effective treatments remains ongoing. One promising contender in this realm is kappa-casein glycomacropeptide (GMP), a milk-derived peptide. Its potential benefits stem from its multifaceted abilities: modulating the gut microbiome, influencing immune responses, impacting gut motility and barrier functions, and binding toxins. These attributes intriguingly align with IBS's pathophysiology, which encompass gut microbiota imbalances, immune system dysregulation and compromised gut barrier functions. The review offers a comprehensive examination of GMP's role in modulating the gut microbiome, focusing on its impact on various bacterial populations, both beneficial and pathogenic. The analysis also addresses the microbial imbalances identified in IBS patients, suggesting that GMP could play a crucial role in restoring a balanced microbial environment and improving overall gut health. Furthermore, the review evaluates GMP's anti-inflammatory capabilities, exploring its impact on specific inflammatory markers and its potential to alleviate the persistent low-grade inflammation associated with IBS. Additionally, it examines recent findings on GMP’s effects on gut motility and barrier health, comparing these insights to the alterations noted in individuals with IBS. Complementing this review, the pilot study assessed the effects of administering a 30 g daily GMP supplement for three weeks to a group of five IBS patients. The study focused on changes in gut microbiota, fecal and blood inflammatory markers and overall gut symptoms. Although the review highlighted promising aspects of GMP, the pilot data revealed a subdued outcome: there was no significant change in fecal microbiota, immune markers exhibited minimal variations, and gut symptoms remained consistent post-GMP supplementation. This dissertation accentuates the potential of GMP as a therapeutic agent for IBS, emphasizing the need for continued investigations to decipher optimal supplementation protocols and to unearth the intricacies of GMP's interactions with gut health.
License
Resource Type
Date Issued
Degree Level
Degree Name
Degree Field
Degree Grantor
Commencement Year
Advisor
Academic Affiliation
Rights Statement
Publisher
Peer Reviewed
Language

Relationships

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details QuYunyao2023.pdf 2023-10-31 Public Download